Prior treatment with at least 1 cytoreductive therapy.
You may not be if
Presence of any hematologic malignancy other than ET.
Major bleeding or thrombosis within the last 3 months prior to study enrollment.
Any prior allogenic or autologous stem-cell transplantation.
Unresolved toxicity ≥ Grade 2 from previous therapy except for stable chronic toxicities (Grade 2) not expected to resolve, such as stable Grade 2 peripheral neuropathy.
Prior nonhematologic malignancy except for the following: Malignancy treated with curative intent and with no evidence of active disease for more than 2 years before screening. Adequately treated carcinoma in situ without current evidence of disease.
Clareo Health | A Phase 3 Study of INCA033989 Versus Best Available Therapy in Participants With Essential Thrombocythemia
